Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
NCT00787527Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2008
- Primary completion
- Dec 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in T-cell non-Hodgkin lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Phase I Maximum Tolerated Dose of Vorinostat at 21 Days, Number of Participants With Dose Limiting Toxicity at 21 Days and 1 more. Started Nov 2008; status: completed.
02
Drugs
vorinostat
03
Conditions
T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00787527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787527.